Combined biologic therapy targeting B cells and eosinophils in relapsing multiple sclerosis and severe asthma: a case report of ofatumumab and mepolizumab.

Aurora Zanghì, Paola Sofia Di Filippo, Claudia Rutigliano, Carlo Avolio, Emanuele D'Amico

Abstract readCase Reports

In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aurora ZanghìBRAND Center, Breakthrough Research in Autoimmune and Neurodegenerative Diseases, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Paola Sofia Di FilippoBRAND Center, Breakthrough Research in Autoimmune and Neurodegenerative Diseases, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Claudia RutiglianoBRAND Center, Breakthrough Research in Autoimmune and Neurodegenerative Diseases, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Carlo AvolioBRAND Center, Breakthrough Research in Autoimmune and Neurodegenerative Diseases, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Emanuele D'AmicoBRAND Center, Breakthrough Research in Autoimmune and Neurodegenerative Diseases, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of multiple sclerosis (MS) in patients with significant comorbidities such as severe asthma presents unique therapeutic challenges. We report a case of successful combined biologic therapy with ofatumumab and mepolizumab in a patient with relapsing MS and pre-existing severe eosinophilic asthma, highlighting the feasibility and safety of dual biologic therapy. To our knowledge, this is the first report of concomitant use of ofatumumab and mepolizumab in a patient with MS and severe eosinophilic asthma, documenting the safety of a non-standard combination strategy in a real-world clinical scenario.

Indexed as

Antibodies, Monoclonal, HumanizedAsthmaBiological TherapyB-LymphocytesEosinophilsMultiple Sclerosis, Relapsing-RemittingHumansTreatment OutcomeAntibodies, Monoclonal, Humanizedmepolizumabofatumumabasthmacombination therapymepolizumabmonoclonal antibodiesmultiple sclerosisofatumumab

Identifiers

PMID41488677

DOI10.3389/fimmu.2025.1634477

PMCPMC12756474

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.